“This points more toward a model where the tumor is cleared and the T cells largely go away,” Hinrichs noted in the interview ...

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, ...

This segment offers an up-to-date overview of current treatment standards and diagnostic practices in advanced esophageal ...

Giredestrant significantly improves IDFS in ER-positive, HER2-negative early-stage breast cancer, surpassing standard ...

The FDA has approved selumetinib (Koselugo) for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

FDA fast track designation facilitates expedited development of DPTX3186, recognizing its potential to address serious unmet medical needs in gastric cancer treatment. DPTX3186 gains FDA fast track ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

Epcoritamab, rituximab, and lenalidomide combination is approved for relapsed/refractory follicular lymphoma, marking a first in bispecific antibody second-line treatments. The EPCORE FL-1 study ...

Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer ...